INS and metabolic dysfunction-associated steatotic liver disease: In this study, hyperglycemia was found to be a central driver of survival risk in patients with MASLD, which exacerbates the process of hepatic lipid deposition and fibrosis through multiple mechanisms, including insulin resistance, oxidative stress, and dysregulation of the gut-liver axis.